{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:30:46Z","timestamp":1793403046210,"version":"4.5.0"},"reference-count":152,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The utilization of immunotherapeutic approaches in the operable settings has demonstrated promising efficacy and safety in preventing postoperative recurrence and improving patients\u2019 survival across various cancer types. To delineate the developmental trajectory and future directions of this specialized field, a comprehensive bibliometric analysis is necessary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods:<\/jats:title>\n                    <jats:p>A total of 541 high-quality publications focusing on the convergence of immunotherapy and surgery were manually extracted from 6973 papers published between 2015 and 2024 in the Web of Science Core Collection. Traditional bibliometric analysis was conducted utilizing VOSviewer, CiteSpace, and the Bibliometrix R package to identify contributions at national and institutional levels, journal impact, and pivotal keywords. The integration of large language model (LLM)-driven text embeddings alongside BERTopic-based semantic modeling enabled a comprehensive synthesis of themes and illuminated prospective directions within this field. Furthermore, advanced dimensionality reduction techniques such as Uniform Manifold Approximation and Projection and t-distributed Stochastic Neighbor Embedding were employed to visualize clustering outcomes and interpret the semantic distances among these academic publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The distribution of publications over time indicated a growing interest in the integration of immunotherapy and surgery. China and the United States were leaders in publication volume and academic influence, while the \u201c\n                      <jats:italic toggle=\"yes\">Journal for Immunotherapy of Cancer<\/jats:italic>\n                      \u201d stands out as a key resource. Clustering based on LLM-driven embedding vectors identified five categories of papers, the thematic classification of which was presented in a hierarchical structure. Further in-depth analysis revealed the optimal utilization patterns of immune checkpoint inhibitors (ICIs) vary across different cancer types. Neoadjuvant ICIs are effective for triple negative breast cancer, non-small cell lung cancer, melanoma, and deficient mismatch repair colon cancer. Adjuvant mRNA vaccines are viable for pancreatic ductal adenocarcinoma and melanoma, while oncolytic virus demonstrate enhanced efficacy alongside manageable toxicity in perioperative settings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This bibliometric analysis, which integrates LLM-driven modeling with manual thematic synthesis, has elucidated the developmental trajectory and future directions of the field concerning the combination of immunotherapy and surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000003231","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T14:30:30Z","timestamp":1758033030000},"page":"9583-9605","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["The convergence of immunotherapy and surgery: a comprehensive bibliographic analysis leveraging large language models"],"prefix":"10.1097","volume":"111","author":[{"given":"Jiahui","family":"Xiang","sequence":"first","affiliation":[{"name":"Eight-year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"},{"name":"Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianzhe","family":"Tian","sequence":"additional","affiliation":[{"name":"Eight-year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"},{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2393-1644","authenticated-orcid":false,"given":"Yiyao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1036-3369","authenticated-orcid":false,"given":"Xin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"R1-20261030","doi-asserted-by":"crossref","first-page":"807\u201321","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"R2-20261030","doi-asserted-by":"crossref","first-page":"670\u201382","DOI":"10.1016\/j.trecan.2022.04.001","article-title":"Utilizing chemokines in cancer immunotherapy","volume":"8","author":"M\u00e4rkl","year":"2022","journal-title":"Trends Cancer"},{"key":"R3-20261030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"R4-20261030","doi-asserted-by":"crossref","first-page":"295\u2013316","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"R5-20261030","doi-asserted-by":"crossref","first-page":"1002\u201314","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"R6-20261030","doi-asserted-by":"crossref","first-page":"188638","DOI":"10.1016\/j.bbcan.2021.188638","article-title":"The progress of immune checkpoint therapy in primary liver cancer","volume":"1876","author":"Zheng","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R7-20261030","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J Clin Invest"},{"key":"R8-20261030","doi-asserted-by":"crossref","first-page":"81\u201395","DOI":"10.1016\/j.semcancer.2022.12.003","article-title":"Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines","volume":"88","author":"Oladejo","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"R9-20261030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"R10-20261030","doi-asserted-by":"crossref","first-page":"3376\u201386","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"R11-20261030","doi-asserted-by":"crossref","first-page":"1710\u201317","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"key":"R12-20261030","doi-asserted-by":"crossref","first-page":"211\u201328","DOI":"10.1038\/s41571-023-00729-2","article-title":"Advancing CAR T cell therapy through the use of multidimensional omics data","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R13-20261030","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1097\/JS9.0000000000002417","article-title":"Prolonged recurrence-free survival by autologous rectronectin-activated killer (RAK) cells in resected high-risk hepatocellular carcinoma: an experimental single-arm Phase II trial (pilot study)","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"R14-20261030","first-page":"Jco2402348","article-title":"Adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic acral lentiginous melanoma","author":"McClelland","year":"2025","journal-title":"J Clin Oncol"},{"key":"R15-20261030","doi-asserted-by":"crossref","first-page":"844\u201375","DOI":"10.1016\/j.jconrel.2022.07.036","article-title":"Breast cancer vaccines: new insights into immunomodulatory and nano-therapeutic approaches","volume":"349","author":"Davodabadi","year":"2022","journal-title":"J Control Release"},{"key":"R16-20261030","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"key":"R17-20261030","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.ctrv.2022.102429","article-title":"Therapeutic cancer vaccines: from biological mechanisms and engineering to ongoing clinical trials","volume":"109","author":"Sobhani","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"R18-20261030","doi-asserted-by":"crossref","first-page":"660\u201370","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat Immunol"},{"key":"R19-20261030","doi-asserted-by":"crossref","first-page":"3236\u201348","DOI":"10.1200\/JCO.22.02575","article-title":"Neoadjuvant checkpoint immunotherapy and melanoma: the time is now","volume":"41","author":"Long","year":"2023","journal-title":"J Clin Oncol"},{"key":"R20-20261030","doi-asserted-by":"crossref","first-page":"586\u201397","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"R21-20261030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"R22-20261030","doi-asserted-by":"crossref","first-page":"1075\u201382","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"R23-20261030","doi-asserted-by":"crossref","first-page":"188593","DOI":"10.1016\/j.bbcan.2021.188593","article-title":"Progress and challenges of immunotherapy in triple-negative breast cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R24-20261030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"key":"R25-20261030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol Cancer"},{"key":"R26-20261030","doi-asserted-by":"crossref","first-page":"100907","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updat"},{"key":"R27-20261030","doi-asserted-by":"crossref","first-page":"45\u201374","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to Anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"R28-20261030","doi-asserted-by":"crossref","first-page":"223\u201349","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"R29-20261030","doi-asserted-by":"crossref","first-page":"720\u201329","DOI":"10.1038\/s12276-022-00784-2","article-title":"Tumor regionalization after surgery: roles of the tumor microenvironment and neutrophil extracellular traps","volume":"54","author":"Kwak","year":"2022","journal-title":"Exp Mol Med"},{"key":"R30-20261030","doi-asserted-by":"crossref","first-page":"1548\u201352","DOI":"10.1158\/0008-5472.CAN-16-1536","article-title":"Surgery for cancer: a trigger for metastases","volume":"77","author":"Tohme","year":"2017","journal-title":"Cancer Res"},{"key":"R31-20261030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"R32-20261030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu","year":"2023","journal-title":"Genome Med"},{"key":"R33-20261030","doi-asserted-by":"crossref","first-page":"1551\u201366","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"R34-20261030","doi-asserted-by":"crossref","first-page":"294\u2013311","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"R35-20261030","doi-asserted-by":"crossref","first-page":"115257","DOI":"10.1016\/j.ejca.2025.115257","article-title":"Neoadjuvant or perioperative immunotherapy for resectable melanoma: the need for biomarkers","volume":"217","author":"Ellebaek","year":"2025","journal-title":"Eur J Cancer"},{"key":"R36-20261030","doi-asserted-by":"crossref","first-page":"12\u201314","DOI":"10.1016\/S1470-2045(24)00627-2","article-title":"Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey","volume":"26","author":"Hauschild","year":"2025","journal-title":"Lancet Oncol"},{"key":"R37-20261030","doi-asserted-by":"crossref","first-page":"1672\u201384","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"R38-20261030","doi-asserted-by":"crossref","first-page":"1756\u201369","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"R39-20261030","doi-asserted-by":"crossref","first-page":"201\u201311","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"Jama"},{"key":"R40-20261030","doi-asserted-by":"crossref","first-page":"429\u201331","DOI":"10.1038\/520429a","article-title":"Bibliometrics: the leiden manifesto for research metrics","volume":"520","author":"Hicks","year":"2015","journal-title":"Nature"},{"key":"R41-20261030","first-page":"1699\u2013710","article-title":"Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis","volume":"110","author":"Zhang","year":"2024","journal-title":"Int J Surg"},{"key":"R42-20261030","first-page":"743\u201344","article-title":"Medical large language model for diagnostic reasoning across specialties","volume":"31","year":"2025","journal-title":"Nat Med"},{"key":"R43-20261030","first-page":"100082","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R44-20261030","doi-asserted-by":"crossref","first-page":"520\u201322","DOI":"10.5195\/jmla.2021.1260","article-title":"EndNote 20 desktop version","volume":"109","author":"Gotschall","year":"2021","journal-title":"J Med Libr Assoc"},{"key":"R46-20261030","doi-asserted-by":"crossref","first-page":"123667","DOI":"10.1016\/j.jenvman.2024.123667","article-title":"Utilizing large language models for identifying future research opportunities in environmental science","volume":"373","author":"Ji","year":"2025","journal-title":"J Environ Manage"},{"key":"R48-20261030","doi-asserted-by":"crossref","first-page":"130303","DOI":"10.1016\/j.energy.2024.130303","article-title":"Demand-side energy management reimagined: a comprehensive literature analysis leveraging large language models","volume":"291","author":"Meng","year":"2024","journal-title":"Energy"},{"key":"R50-20261030","doi-asserted-by":"crossref","first-page":"523\u201338","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: vOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"R52-20261030","first-page":"5303\u201310","article-title":"Searching for intellectual turning points: progressive knowledge domain visualization","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"R53-20261030","doi-asserted-by":"crossref","first-page":"359\u201377","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Technol"},{"key":"R55-20261030","doi-asserted-by":"crossref","first-page":"1383\u2013+","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"key":"R56-20261030","doi-asserted-by":"crossref","first-page":"1382\u201399","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discovery"},{"key":"R57-20261030","doi-asserted-by":"crossref","first-page":"822\u201335","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"R58-20261030","doi-asserted-by":"crossref","first-page":"0011","DOI":"10.1038\/s41551-016-0011","article-title":"In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy","volume":"1","author":"Wang","year":"2017","journal-title":"Nat Biomed Eng"},{"key":"R59-20261030","doi-asserted-by":"crossref","first-page":"1976\u201386","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"R60-20261030","doi-asserted-by":"crossref","first-page":"1655\u2013+","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nature Med"},{"key":"R61-20261030","doi-asserted-by":"crossref","first-page":"3353\u2013+","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"R62-20261030","doi-asserted-by":"crossref","first-page":"1853\u201360","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"key":"R63-20261030","doi-asserted-by":"crossref","first-page":"eaar1916","DOI":"10.1126\/scitranslmed.aar1916","article-title":"Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases","volume":"10","author":"Park","year":"2018","journal-title":"Sci Trans Med"},{"key":"R64-20261030","doi-asserted-by":"crossref","first-page":"eaao1641","DOI":"10.1126\/scitranslmed.aao1641","article-title":"Neoadjuvant oncolytic virotherapy before surgery sensitizes triple- negative breast cancer to immune checkpoint therapy","volume":"10","author":"Bourgeois-Daigneault","year":"2018","journal-title":"Sci Trans Med"},{"key":"R65-20261030","doi-asserted-by":"crossref","first-page":"477\u2013+","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nature Med"},{"key":"R66-20261030","doi-asserted-by":"crossref","first-page":"89\u2013+","DOI":"10.1038\/s41565-018-0319-4","article-title":"In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment","volume":"14","author":"Chen","year":"2019","journal-title":"Nature Nanotechnol"},{"key":"R67-20261030","doi-asserted-by":"crossref","first-page":"1279\u201388","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"key":"R68-20261030","doi-asserted-by":"crossref","first-page":"566\u2013+","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nature Med"},{"key":"R69-20261030","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41565-020-00781-4","article-title":"A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy","volume":"15","author":"Xu","year":"2020","journal-title":"Nature Nanotechnol"},{"key":"R70-20261030","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nature Med"},{"key":"R71-20261030","doi-asserted-by":"crossref","first-page":"439\u201346","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Europ Urol"},{"key":"R72-20261030","doi-asserted-by":"crossref","first-page":"1563\u201370","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"key":"R73-20261030","doi-asserted-by":"crossref","first-page":"432\u2013+","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"R74-20261030","doi-asserted-by":"crossref","first-page":"813\u201323","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"R75-20261030","doi-asserted-by":"crossref","first-page":"522\u201330","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"R76-20261030","doi-asserted-by":"crossref","first-page":"810\u201321","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"R77-20261030","doi-asserted-by":"crossref","first-page":"1973\u201385","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"R78-20261030","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.1016\/S0140-6736(00)02654-4","article-title":"Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial","volume":"356","author":"Takayama","year":"2000","journal-title":"Lancet"},{"key":"R79-20261030","doi-asserted-by":"crossref","first-page":"171\u201378","DOI":"10.1007\/s00534-011-0437-y","article-title":"Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma","volume":"19","author":"Shimizu","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R80-20261030","doi-asserted-by":"crossref","first-page":"970\u201376","DOI":"10.4161\/hv.27678","article-title":"Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma","volume":"10","author":"Shimizu","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R81-20261030","doi-asserted-by":"crossref","first-page":"2251\u201359","DOI":"10.1007\/s00262-012-1289-2","article-title":"Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer","volume":"61","author":"Shi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"R82-20261030","first-page":"3221\u201330","article-title":"MHC I-related chain a expression in gastric carcinoma and the efficacy of immunotherapy with cytokine-induced killer cells","volume":"5","author":"Chen","year":"2015","journal-title":"Am J Cancer Res"},{"key":"R83-20261030","doi-asserted-by":"crossref","first-page":"e93886","DOI":"10.1371\/journal.pone.0093886","article-title":"Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients","volume":"9","author":"Gao","year":"2014","journal-title":"PLoS One"},{"key":"R84-20261030","doi-asserted-by":"crossref","first-page":"251\u201359","DOI":"10.1007\/s12026-015-8743-0","article-title":"Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer","volume":"64","author":"Chen","year":"2016","journal-title":"Immunol Res"},{"key":"R85-20261030","first-page":"31318\u201328","article-title":"Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"key":"R86-20261030","doi-asserted-by":"crossref","first-page":"e944927","DOI":"10.12659\/MSM.944927","article-title":"Editorial: first regulatory approval for adoptive cell therapy with autologous Tumor-Infiltrating Lymphocytes (TILs) - lifileucel (Amtagvi)","volume":"30","author":"Parums","year":"2024","journal-title":"Med Sci Monit"},{"key":"R87-20261030","doi-asserted-by":"crossref","first-page":"916\u201329","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol"},{"key":"R88-20261030","doi-asserted-by":"crossref","first-page":"144\u201350","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"R89-20261030","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/2159-8290.CD-NB2023-0028","article-title":"mRNA vaccine slows melanoma recurrence","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"key":"R90-20261030","doi-asserted-by":"crossref","first-page":"632\u201344","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"R91-20261030","doi-asserted-by":"crossref","first-page":"450\u201357","DOI":"10.1038\/s41591-023-02309-4","article-title":"Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial","volume":"29","author":"Soliman","year":"2023","journal-title":"Nat Med"},{"key":"R92-20261030","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41392-024-02029-2","article-title":"Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R93-20261030","doi-asserted-by":"crossref","first-page":"1789\u201396","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat Med"},{"key":"R94-20261030","doi-asserted-by":"crossref","first-page":"e003119","DOI":"10.1136\/jitc-2021-003119","article-title":"Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB\/II trial","volume":"9","author":"Monga","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R95-20261030","doi-asserted-by":"crossref","first-page":"1012\u201318","DOI":"10.1158\/1078-0432.CCR-20-3105","article-title":"A phase I trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer","volume":"27","author":"Soliman","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R96-20261030","doi-asserted-by":"crossref","first-page":"e010833","DOI":"10.1136\/jitc-2024-010833","article-title":"Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care","volume":"13","author":"Topalian","year":"2025","journal-title":"J Immunother Cancer"},{"key":"R97-20261030","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"R98-20261030","doi-asserted-by":"crossref","first-page":"112903","DOI":"10.1016\/j.intimp.2024.112903","article-title":"Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: a comprehensive review","volume":"141","author":"Cui","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R99-20261030","doi-asserted-by":"crossref","first-page":"101412","DOI":"10.1016\/j.xcrm.2024.101412","article-title":"Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma","volume":"5","author":"Pulliam","year":"2024","journal-title":"Cell Rep Med"},{"key":"R100-20261030","doi-asserted-by":"crossref","first-page":"1696\u2013708","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"R101-20261030","doi-asserted-by":"crossref","first-page":"219\u201329","DOI":"10.1016\/S2468-1253(21)00385-X","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","volume":"7","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R102-20261030","doi-asserted-by":"crossref","first-page":"422\u201331","DOI":"10.1016\/S2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R103-20261030","doi-asserted-by":"crossref","first-page":"3223\u201335","DOI":"10.1038\/s41591-024-03249-3","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial","volume":"30","author":"Nederlof","year":"2024","journal-title":"Nat Med"},{"key":"R104-20261030","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ccell.2024.10.007","article-title":"Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: a prospective phase II trial","volume":"42","author":"Davar","year":"2024","journal-title":"Cancer Cell"},{"key":"R105-20261030","doi-asserted-by":"crossref","first-page":"420\u201330","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"key":"R106-20261030","first-page":"1649\u201354","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"key":"R107-20261030","doi-asserted-by":"crossref","first-page":"454\u201361","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"R108-20261030","doi-asserted-by":"crossref","first-page":"1602\u201311","DOI":"10.1038\/s41591-024-02965-0","article-title":"Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial","volume":"30","author":"Schuler","year":"2024","journal-title":"Nat Med"},{"key":"R109-20261030","doi-asserted-by":"crossref","first-page":"909\u201320","DOI":"10.1016\/j.jtho.2022.04.012","article-title":"Three-year follow-up of neoadjuvant programmed cell death protein-1 inhibitor (Sintilimab) in NSCLC","volume":"17","author":"Zhang","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R110-20261030","doi-asserted-by":"crossref","first-page":"816\u201326","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC","volume":"15","author":"Gao","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R111-20261030","doi-asserted-by":"crossref","first-page":"3284\u201390","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat Med"},{"key":"R112-20261030","doi-asserted-by":"crossref","first-page":"1949\u201358","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair\u2013deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"R113-20261030","doi-asserted-by":"crossref","first-page":"2476\u201387","DOI":"10.1200\/JCO.20.00201","article-title":"Neoadjuvant nivolumab for patients with resectable merkel cell carcinoma in the CheckMate 358 trial","volume":"38","author":"Topalian","year":"2020","journal-title":"J Clin Oncol"},{"key":"R114-20261030","doi-asserted-by":"crossref","first-page":"1023\u201334","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat Med"},{"key":"R115-20261030","first-page":"2068\u201378","article-title":"Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial","volume":"29","author":"Yin","year":"2023","journal-title":"Nat Med"},{"key":"R116-20261030","doi-asserted-by":"crossref","first-page":"212\u201322","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"R117-20261030","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun"},{"key":"R118-20261030","doi-asserted-by":"crossref","first-page":"e002568","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R119-20261030","doi-asserted-by":"crossref","first-page":"1773\u201386","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"R120-20261030","doi-asserted-by":"crossref","first-page":"9350","DOI":"10.1038\/s41467-024-53704-5","article-title":"Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial","volume":"15","author":"Pan","year":"2024","journal-title":"Nat Commun"},{"key":"R121-20261030","doi-asserted-by":"crossref","first-page":"208\u201318","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R122-20261030","doi-asserted-by":"crossref","first-page":"144\u201351","DOI":"10.1038\/s41591-024-03411-x","article-title":"Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1\/2 trial","volume":"31","author":"Dummer","year":"2025","journal-title":"Nat Med"},{"key":"R123-20261030","doi-asserted-by":"crossref","first-page":"155\u201360","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"key":"R124-20261030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/jamaoncol.2025.0081","article-title":"Neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation therapy in HPV-negative head and neck cancer: the DEPEND phase 2 nonrandomized clinical trial","volume":"11","author":"Rosenberg","year":"2025","journal-title":"JAMA Oncol"},{"key":"R125-20261030","doi-asserted-by":"crossref","first-page":"1563\u201375","DOI":"10.1016\/S1470-2045(24)00504-7","article-title":"Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol"},{"key":"R126-20261030","first-page":"464\u201374","article-title":"Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05)","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"R127-20261030","doi-asserted-by":"crossref","first-page":"255\u201365","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II Study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"R128-20261030","doi-asserted-by":"crossref","first-page":"1453\u201364","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol"},{"key":"R129-20261030","doi-asserted-by":"crossref","first-page":"504\u201313","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"R130-20261030","doi-asserted-by":"crossref","first-page":"119\u201329","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir Med"},{"key":"R131-20261030","doi-asserted-by":"crossref","first-page":"1240\u201352","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"R132-20261030","doi-asserted-by":"crossref","first-page":"1981\u201391","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"R133-20261030","doi-asserted-by":"crossref","first-page":"2946\u201356","DOI":"10.1200\/JCO.21.02772","article-title":"Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast cancer: primary results of the randomized phase III IMpassion050 trial","volume":"40","author":"Huober","year":"2022","journal-title":"J Clin Oncol"},{"key":"R134-20261030","doi-asserted-by":"crossref","first-page":"1038\u201352","DOI":"10.1016\/S1470-2045(24)00211-0","article-title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study","volume":"25","author":"Allaf","year":"2024","journal-title":"Lancet Oncol"},{"key":"R135-20261030","first-page":"381:e071674","article-title":"Advances in systemic therapies for triple negative breast cancer","author":"Leon-Ferre","year":"2023","journal-title":"Bmj"},{"key":"R136-20261030","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1038\/s41467-024-47000-5","article-title":"Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma","volume":"15","author":"Le Saux","year":"2024","journal-title":"Nat Commun"},{"key":"R137-20261030","doi-asserted-by":"crossref","first-page":"1353\u201365","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"R138-20261030","doi-asserted-by":"crossref","first-page":"256\u201363","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"key":"R139-20261030","doi-asserted-by":"crossref","first-page":"929\u201338","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"R140-20261030","doi-asserted-by":"crossref","first-page":"2559\u201369","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"key":"R141-20261030","doi-asserted-by":"crossref","first-page":"e005320","DOI":"10.1136\/jitc-2022-005320","article-title":"Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy","volume":"10","author":"Casarrubios","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R142-20261030","doi-asserted-by":"crossref","first-page":"e007667","DOI":"10.1136\/jitc-2023-007667","article-title":"Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)","volume":"11","author":"Pellegrino","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R143-20261030","doi-asserted-by":"crossref","first-page":"e010041","DOI":"10.1136\/jitc-2024-010041","article-title":"Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy","volume":"12","author":"Ji","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R144-20261030","doi-asserted-by":"crossref","first-page":"e70211","DOI":"10.1002\/mco2.70211","article-title":"Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy versus neoadjuvant chemotherapy in non-small cell lung cancer treatment: a mixed method meta-analysis based on global randomized controlled trials","volume":"6","author":"Li","year":"2025","journal-title":"MedComm (2020)"},{"key":"R145-20261030","doi-asserted-by":"crossref","first-page":"491\u2013503","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"R146-20261030","doi-asserted-by":"crossref","first-page":"1453\u201362","DOI":"10.1200\/JCO-24-02239","article-title":"Neoadjuvant nivolumab plus ipilimumab versus chemotherapy in resectable lung cancer","volume":"43","author":"Awad","year":"2025","journal-title":"J Clin Oncol"},{"key":"R147-20261030","doi-asserted-by":"crossref","first-page":"e009799","DOI":"10.1136\/jitc-2024-009799","article-title":"Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study","volume":"12","author":"Bahce","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R148-20261030","doi-asserted-by":"crossref","first-page":"1271\u201377","DOI":"10.1001\/jamaoncol.2022.2310","article-title":"Response rate and safety of a neoadjuvant pertuzumab, atezolizumab, docetaxel, and trastuzumab regimen for patients with ERBB2-positive stage II\/III breast cancer: the Neo-PATH phase 2 nonrandomized clinical trial","volume":"8","author":"Ahn","year":"2022","journal-title":"JAMA Oncol"},{"key":"R149-20261030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R150-20261030","doi-asserted-by":"crossref","first-page":"1344\u201357","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"R151-20261030","doi-asserted-by":"crossref","first-page":"907\u201319","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann Oncol"},{"key":"R152-20261030","doi-asserted-by":"crossref","first-page":"1274\u201386","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"R153-20261030","doi-asserted-by":"crossref","first-page":"285\u201395","DOI":"10.1016\/j.jtho.2024.09.1443","article-title":"Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis","volume":"20","author":"Marinelli","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R154-20261030","doi-asserted-by":"crossref","first-page":"217\u201326","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"R155-20261030","doi-asserted-by":"crossref","first-page":"1696\u201398","DOI":"10.1200\/JCO.22.00503","article-title":"Use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer: ASCO guideline rapid recommendation update","volume":"40","author":"Korde","year":"2022","journal-title":"J Clin Oncol"},{"key":"R156-20261030","doi-asserted-by":"crossref","first-page":"1835\u201347","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"R157-20261030","doi-asserted-by":"crossref","first-page":"708\u201315","DOI":"10.1038\/s41591-023-02786-7","article-title":"Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000003231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:02:26Z","timestamp":1793401346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000003231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":152,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000003231","relation":{},"ISSN":["1743-9159","1743-9191"],"issn-type":[{"value":"1743-9159","type":"electronic"},{"value":"1743-9191","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"2025-04-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}